[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-metastatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-metastatic":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,76,110,132,156,185,215,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100638863","phase-3-bl-m14d1-plus-atezolizumab-vs-standard-of-care-in-first-line-extensive-stage-small-cell-lung-cancer-brendell-lung01-100638863",false,"NCT07625644","BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)","A Phase 3 Open-Label, Randomized Controlled Trial of BL-M14D1 and Atezolizumab vs. Standard-of-Care Therapy in Patients With First-Line Extensive-Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed first-line (1L), extensive-stage (ES) small cell lung cancer (SCLC)\n* Must be eligible to receive a platinum-based chemotherapy regimen in combination with an anti-PD-L1 inhibitor.\n* At least one measurable lesion based on RECIST v1.1 per investigator assessment.\n* An Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Received any kind of platinum or etoposide treatment for limited stage (LS) SCLC within 6 months prior to enrollment.\n* Participants who have received prior topoisomerase inhibitor-based ADC therapy.\n* Participants with history of severe heart disease\n* Participants with active autoimmune diseases and inflammatory diseases,\n* Participants with other prior or concurrent malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and\u002For carcinoma in situ after adequate resection, or other malignancy treated with curative intent with a disease-free interval of at least 3 years\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.","ALL","18 Years",{"count":19,"type":20},550,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).",[26,27,28,29,30,31,32,33],"Small Cell Lung Cancer Extensive Stage","Small-cell Lung Cancer","Small Cell Carcinoma","Sclc","SCLC,Extensive Stage","Lung Cancer","Lung Cancer Metastatic","Lung Cancer Stage IV",[35,36],"DLL3","First Line","NOT_YET_RECRUITING","2026-07-14",{"date":40,"type":41},"2026-07-16","ACTUAL",{"date":43,"type":20},"2026-06",{"date":45,"type":20},"2031-06",{"name":47,"class":48},"SystImmune Inc.","INDUSTRY",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100558176","primary-tumor-resection-for-m1a-stage-lung-cancer-100558176","NCT06547710","Primary Tumor Resection for M1a Stage Lung Cancer","Primary Tumor Resection for M1a Stage Lung Cancer With Occult Pleural Dissemination Discovered During Surgery: a Prospective, Single-arm, Multi-center, Phase Ⅱ Trial","ECTOP-1023","Inclusion Criteria:\n\n1. Volunteer to participate in clinical research, willing to follow and able to complete all trial procedures;\n2. Aged 18-80 years (including critical values) when signing the informed consent form;\n3. ECOG score 0 or 1;\n4. No previous lung cancer surgery;\n5. Intraoperative or postoperative pathological confirmation of M1a stage lung cancer;\n6. Occult pleural metastasis found during surgery;\n7. First-time treatment and no radiotherapy or chemotherapy.\n\nExclusion Criteria:\n\n1. The lesion cannot be completely removed surgically;\n2. Cytological or histological pathology confirms other lung malignancies other than lung cancer;\n3. Patients who have undergone lung cancer surgery before;\n4. Patients who have received radiotherapy or chemotherapy and are not treatment-naive patients.","75 Years",{"count":59,"type":20},66,"OBSERVATIONAL","This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1023. This study aims to explore the safety and efficacy of primary lesion resection in the treatment of M1a stage lung cancer with pleural dissemination found during surgery, and to more accurately evaluate whether primary lesion resection can improve the OS and quality of life of the corresponding patients.",[32,63],"Surgical Resection","RECRUITING","2026-07-05",{"date":67,"type":41},"2026-07-08",{"date":69,"type":41},"2024-04-01",{"date":71,"type":20},"2027-12",{"name":73,"class":74},"Fudan University","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},"100471453","phase-2-a-study-of-stereotactic-radiosurgery-srs-for-people-with-lung-cancer-that-has-spread-to-the-brain-100471453","NCT05419076","A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain","A Single Arm Phase II Study Assessing Efficacy of Stereotactic Radiosurgery (SRS) for Brain Metastasis (BM) From Small Cell Lung Cancer (SCLC)","Inclusion Criteria:\n\n* Histologic diagnosis of small cell lung cancer\n* Radiographic diagnosis of up to 20 brain metastases on contrast-enhanced MRI\n* Age 18 and above\n* Performance status KPS 60-100\u002FECOG 0-2\n* Female patients must be of non-reproductive potential or have a negative serum pregnancy test at the time of enrollment\n* The patient or legally authorized representative is able to provide informed consent\n\nExclusion Criteria:\n\n* Unable to undergo contrast-enhanced MRI brain\n* Leptomeningeal disease confirmed on lumbar puncture, MRI brain, or MRI spine\n* Pregnant or lactating women\n* Prior brain-directed radiotherapy\n* Uncontrolled systemic disease without reasonable systemic therapy options felt likely to result in death as observed on CT or PET\u002FCT imaging, no more than 3 months before study enrollment",{"count":84,"type":20},62,[86],"PHASE2","The purpose of the study is to see if stereotactic radiosurgery\u002FSRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer\u002FSCLC.",[31,32,89,90,27,91],"Brain Metastases","Brain Metastases, Adult","Small Cell Lung Carcinoma",[93,94,95,96,97,98,99,100],"Stereotactic Radiosurgery","small cell lung cancer","small cell lung carcinoma","lung cancer","lung cancer metastatic","brain metastases","22-133","Memorial Sloan Kettering Cancer Center","2026-06-09",{"date":103,"type":41},"2026-06-10",{"date":105,"type":41},"2022-06-10",{"date":107,"type":20},"2027-06-10",{"name":100,"class":74},7,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100631009","phase-1-phase-1b-trial-of-intratumoral-cisplatin-for-stage-iv-lung-cancer-100631009","NCT07495098","Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer","2.5.1 Inclusion criteria\n\n* Age 18 years or above\n* Eastern Cooperative Oncology Group (ECOG) performance score 0-2\n* Have known or suspected metastatic NSCLC at time of enrollment (including patients who progress on initial therapy or are found to have metastatic disease during therapy and are not excluded\n* Patient is able and willing to provide informed consent.\n* Rapid on-site cytopathologic examination (ROSE) performed during the procedure (if not previously diagnosed) and returns likely NSCLC. No injection will be performed if ROSE is non-diagnostic.\n* A CT scan of the chest (with or without contrast) within the prior 3 months.\n* The presence of an EBUS accessible target site determined by a treating investigator. These may be primary lung cancers or metastatic sites (including when a lymph node station has been replaced by metastatic tumor), that are accessible by EBUS.\n* MDC agreement of likely Stage IV NSCLC (confirmation from at minimum a Medical Oncologist and Radiation Oncologist on clinical stage).\n* Patients must have adequate organ and marrow function as defined below:\n\n  * Leukocytes ≥3,000\u002FmcL\n  * Platelets ≥100,000\u002FmcL\n  * Total bilirubin ≤ institutional upper limit of normal (ULN)\n  * AST(SGOT)\u002FALT(SGPT) ≤ institutional ULN\n  * Creatinine ≤ institutional ULN\n\n2.5.2 Exclusion criteria\n\n* Use of an investigational agent in prior 30 days\n* Pregnancy\u002Flactation (pregnancy test to be performed by pre-op as part of standard of care for women of child-bearing age as defined by UVMMC Policy NPREP16)\n* Treatment with intravenous cytotoxic chemotherapy within the past 14 days\n* Allergy to cisplatin or its derivatives\n* Allergy to iodinated contrast\n* Patient not appropriate for the research study based on physician discretion",{"count":117,"type":20},12,[119],"PHASE1","The addition of intravenous (given through a vein) cisplatin to immunotherapy improves treatment outcomes for lung cancer, but unfortunately results in significantly more side effects since the rest of the body is exposed to significant amounts of the drug. Our clinical trial data indicate that injecting cisplatin directly into the tumor using a bronchoscope (a small flexible tube with a camera in it) has very few side effects, and results in significant cell death and potentially improvement in the immune response. The goal of this proposal is to evaluate a computational approach, that incorporates data from a CT scan, to determine the optimal dose and delivery location within a tumor to maximize tumor cell killing and the immune response.",[32,122],"Lung Cancer (NSCLC)","2026-03-20",{"date":125,"type":41},"2026-03-27",{"date":127,"type":20},"2026-07-01",{"date":129,"type":20},"2031-06-30",{"name":131,"class":74},"University of Vermont",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":75},"100473985","phase-1-fluorine-18-alphavbeta6-binding-peptide-positron-emission-tomography-in-metastatic-non-small-cell-lung-cancer-100473985","NCT05452005","Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer","Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography for Staging, Response Assessment, and Patient Selection in Metastatic Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Men and women age \\>18 yrs\n2. Biopsy proven NSCLC with brain metastases (treated or untreated)\n3. Life-expectancy of ≥3 months in the opinion of the treating physician\n4. Available archival tumor tissue (excisional, core, or fine needle aspiration (FNA) is acceptable). Tissue from a metastatic site is preferred when available.\n5. Able to tolerate all study procedures, including remain motionless for up to 30-60 minutes per scan\n6. Ability to understand and willingness to sign a written informed consent document.\n7. Planned to undergo additional cancer-directed therapy followed by standard-of-care re-staging imaging\n8. \\[18F\\]-FDG PET\u002FCT within 21 days of enrollment\n9. MRI brain within 21 days of enrollment\n10. Eastern Cooperative Oncology Group Performance Status ≤ 2\n11. Glomerular filtration rate (GFR) ≥ 60\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Prisoners\n3. Concurrent malignancy of a different histology that could confound imaging interpretation\n4. Patients who cannot undergo PET\u002FCT scanning because of weight limits(\\>350lbs)",{"count":140,"type":20},20,[119],"This study investigates fluorine-18-AlphaVBeta6-BP (\\[18F\\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \\[18F\\]-αvβ6-BP PET\u002FComputed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.",[31,32,89,144],"Non Small Cell Lung Cancer",[146],"Positron Emission Tomography","2026-02-23",{"date":149,"type":41},"2026-02-27",{"date":151,"type":41},"2022-09-13",{"date":153,"type":20},"2026-12-31",{"name":155,"class":74},"University of California, Davis",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":166,"briefSummary":167,"conditions":168,"keywords":172,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":184},"100533631","phase-1-a-study-assessing-kb707-for-the-treatment-of-advanced-solid-tumor-malignancies-affecting-the-lungs-100533631","NCT06228326","A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","KB707-02: A Phase 1\u002F2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs","KYANITE-1","Key Inclusion Criteria:\n\n* Age 18 years or older at the time of informed consent\n* Life expectancy \\>12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have at least one measurable lung lesion per RECIST v1.1 at Screening\n* Cohorts 1 through 4 only: Histologically confirmed diagnosis of advanced solid tumor malignancy affecting the lungs and the individual has progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or has no standard of care therapy.\n* Cohorts 5, 6, and 7 only: (1) Histologically or cytologically confirmed diagnosis of stage 3 or 4 NSCLC, as per American Joint Committee on Cancer (AJCC) staging system (8th edition) and (2) Subject must meet the following criteria of prior lines of therapy:\n\n  1. Subject has previously received no more than one line of prior immune checkpoint inhibitor (ICI) with or without platinum-based chemotherapy, or no more than two prior lines of therapy when given the ICI and platinum-based chemotherapy sequentially as two separate lines.\n  2. Subjects with an actionable mutation (e.g., EGFR, KRAS, ALK, or ROS1 genomic alteration), are permitted to have received one additional line of approved targeted therapy.\n\nKey Exclusion Criteria:\n\n* Not fully recovered from prior surgery or radiotherapy, including all radiation-related toxicities\n* The subject is pregnant, nursing, or plans to become pregnant during study treatment and through three months after the last dose of KB707\n* Have known history of positive human immunodeficiency virus (HIV 1\u002F2)\n* Cohorts 5, 6, and 7 only:\n\n  1. Subject has a known additional malignancy that is progressing or requires active treatment\n  2. Subject has active brain metastases or leptomeningeal metastases\n  3. Prior anti-PD-1\u002FPD-L1 therapy was intolerable and required discontinuation of treatment\n  4. Subject has active, known, or suspected autoimmune disease requiring systemic treatment\n  5. Subject has known acute or chronic hepatitis\n  6. Subject has active pneumonitis or history of ICI-induced pneumonitis that required steroids",{"count":165,"type":20},250,[119,86],"The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs of subjects with advanced solid tumor malignancies.\n\nThis is a Phase 1\u002F2, open-label, multicenter, dose escalation and expansion study designed to evaluate the safety, tolerability, preliminary efficacy, and immunologic effect of KB707.\n\nMonotherapy KB707 dose escalation and expansion cohorts enrolled adults with advanced solid tumor malignancies affecting the lungs who had progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy. The dose escalation phase (Cohorts 1 and 2) evaluated KB707 monotherapy using a standard 3+3 design, followed by a dose expansion phase (Cohort 4) to further evaluate the selected dose. Subjects received inhaled KB707 weekly for three weeks, then every three weeks. The dose escalation portion of the study is now complete, and the selected dose is being evaluated in the expansion phase.\n\nCombination regimens with a selected (fixed) dose of KB707 are being evaluated in subjects with advanced or metastatic non-small cell lung cancer (NSCLC). Subjects in Cohorts 5 and 6 are receiving inhaled KB707 once every 2 weeks (q2w), delivered in combination with Keytruda once every 6 weeks. Subjects in Cohort 7 are receiving inhaled KB707 in combination with docetaxel once every 3 weeks.\n\nAll subjects will be treated until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.",[169,32,170,171,122],"Lung Cancer, Non-small Cell","Solid Tumor, Adult","Advanced Cancer",[173,174,96],"cancer","Krystal Biotech","2025-10-22",{"date":177,"type":41},"2025-10-24",{"date":179,"type":41},"2024-04-17",{"date":181,"type":20},"2028-07",{"name":183,"class":48},"Krystal Biotech, Inc.",14,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":21,"phases":194,"briefSummary":196,"conditions":197,"keywords":201,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":75},"100594950","clinical-application-study-of-petct-for-differential-diagnosis-of-non-small-cell-lung-cancer-100594950","NCT07026110","Clinical Application Study of PET\u002FCT for Differential Diagnosis of Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Age 18-80 years;\n2. Imaging studies suspecting non-small cell lung cancer;\n3. Solid lung nodules (≥8 mm in diameter) diagnosed by chest ct, which are subject to 18F-FDG PET\u002FCT and surgical resection\u002Fbiopsy of lung nodules according to the NCCN guideline specifications for NSCLC in the 2024 edition;\n4. Patients or family members agreed to participate in this clinical study and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Women during pregnancy and lactation;\n2. Persons with a history of surgery and trauma that significantly affects metabolic distribution and anatomical structure;\n3. Persons with severe other systemic diseases or known hypersensitivity to humanized monoclonal antibody products;\n4. Patient is unable to cooperate in completing the PET\u002FCT examination;\n5. Patient has participated in other clinical studies within the past year that have resulted in radiation exposures in excess of an effective dose of 50 mSv, in addition to the radiation exposures anticipated from participation in this clinical study;\n6. Patient should not participate in this clinical trial in the opinion of the investigator.","80 Years",{"count":193,"type":20},100,[195],"NA","This study aims to explore the efficacy of Trop2, EpCAM-specific PET\u002FCT imaging for noninvasive visualization of Trop2 or EpCAM expression levels in non-small cell lung cancer; and to explore the differences between novel target-specific PET\u002FCT examinations and conventional 18F-FDG PET\u002FCT in the diagnosis and differential diagnosis of solid lung nodules.",[31,198,199,32,200],"Lung Diseases","Lung Neoplasms","Lung Inflammation",[202,203,204,205],"Trophoblast cell surface antigen 2 (Trop2)","Epithelial cell adhesion molecule(EpCAM)","ImmunoPET","Lung tumor","2025-06-10",{"date":208,"type":41},"2025-06-18",{"date":210,"type":41},"2024-12-23",{"date":212,"type":20},"2026-10-31",{"name":214,"class":74},"RenJi Hospital",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":223,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":21,"phases":227,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":75},"100557430","phase-1-til-therapy-combined-with-pembrolizumab-for-advanced-or-metastatic-refractory-lung-cancer-100557430","NCT06538012","TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer","Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes (TIL) Therapy Combined With Pembrolizumab Immunotherapy in Patients With Advanced or Metastatic Refractory Lung Cancer","BAH2472","Inclusion Criteria:\n\n* Age: 16 years to 90 years\n* Histologically diagnosed as primary\u002Frelapsed\u002Fmetastasized Lung cancer\n* Expected life span more than 3 months\n* Karnofsky≥60% or ECOG score 0-2\n* Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.\n* Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated\n* At least 1 evaluable tumor lesion\n* Hematology and Chemistry（within 7 days prior to enrollment）:\n* Absolute count of white blood cells≥2.5×10\\^9\u002FL\n* Absolute count of neutropils≥1.5×10\\^9\u002FL\n* Absolute count of lymphocytes ≥0.7×109\u002FL\n* Platelet count≥100×10\\^9\n* hemoglobin≥90 g\u002FL\n* Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days)\n* International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days)\n* Serum creatinine ≤1.5mg\u002FdL(or ≤132.6μmol\u002FL), or clearance rate≥50mL\u002Fmin\n* Serum ALT\u002FAST ≤3×ULN(subjects with liver metastasis ≤3×ULN)\n* Totol bilirubin≤1.5×ULN\n* No absolute or relative contraindications to operation or biopsy\n* Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent and continue within 1 year after the completion of lymphodepletion\n* Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy, and biologics must cease 28 days before obtaining TILs\n* Be able to understand and sign the informed consent document;\n* Be able to stick to follow-up visit plan and other requirements in the agreement.\n\nExclusion Criteria:\n\n* Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment\n* Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%\n* Significant cardiovascular anomalies according to any of the following definitions:\n* New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant\n* Low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrioventricular conductive block, etc.\n* Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and\u002For anti-HCV positive), syphilis infection or Treponema pallidum antibody positive.\n* Severe physical or mental diseases;\n* Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection).\n* Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy.\n* History of allergy to chemical compounds consisting of chemical and biological substances resembling cell therapy.\n* Having received immunotherapy and developed an irAE level greater than Level 3.\n* Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded).\n* Females in pregnancy or lactation. History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy.\n* Researchers consider the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.","16 Years","90 Years",{"count":226,"type":20},85,[119,86],"This Phase I\u002FII study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with advanced or metastatic refractory lung cancer. Lifileucel (Amtagvi), the first FDA-approved TIL therapy, has demonstrated significant success in treating unresectable or metastatic melanoma by utilizing the patient's own immune cells to combat cancer. This study aims to apply a similar approach to lung cancer. TILs will be harvested from patients' tumors, expanded in vitro, and infused back into the patients following a non-myeloablative lymphodepletion regimen. Pembrolizumab, a monoclonal antibody targeting the PD-1 receptor on T cells, will be administered to enhance the immune response. The primary endpoint is to determine the objective response rate (ORR) of this combined therapy. Secondary endpoints include disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and quality of life (QoL). This trial aims to offer a novel, personalized treatment option for patients with limited therapeutic alternatives.",[31,32,169,230],"Lung Cancer Recurrent",[232,233,234,235,236,237],"Tumor Infiltrating Lymphocytes","CAR-T CELL","Biological Therapy","Advanced or Metastatic Refractory","Immunotherapy","TIL","2024-10-11",{"date":240,"type":41},"2024-10-15",{"date":242,"type":41},"2024-08-20",{"date":244,"type":20},"2026-12-28",{"name":246,"class":74},"Essen Biotech",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":255,"conditions":256,"keywords":259,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":271},"100480587","i3lung-integrative-science-intelligent-data-platform-for-individualized-lung-cancer-care-with-immunotherapy-100480587","NCT05537922","I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy","Inclusion Criteria:\n\n* Age \\>\u002F= 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C\u002F= 2.\n* Histologically confirmed diagnosis of stage IIIB\u002FC-IV Non-Small-Cell Lung Cancer\n* Received any line immunotherapy (maintenance therapy with Durvalumab is allowed) for retrospective cohort; clinical indication for frontline treatment with immunotherapy as first line treatment for prospective cohort.\n* Patients with CNS metastasis are allowed\n* Patients with driver genomic alterations are allowed (only for retrospective cohort)\n* Evidence of a personally signed and dated ICF indicating that the patient has been informed of and understands all pertinent aspects of the study before enrolment (only for prospective cohort)\n* Availability of at least one FFPE block for -omics data generation (only for prospective cohort)\n\nExclusion Criteria:\n\n* Patients without minimal treatment information data to be included in the retrospective cohort\n* Prior treatment for advanced disease (only for prospective cohort)\n* Unavailability or inability to comply with the requested study procedures, including compilation of QoL questionnaires",{"count":254,"type":20},2200,"I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource data (real word and multi-omics data). This objective will be reached through a retrospective - setting up a transnational platform of available data from 2000 patients - and a prospective - multi-omics prospective data collection in 200 NSCLS patients - study phase.\n\nThe retrospective cohort will be used to perform a preliminary knowledge extraction phase and to build a retrospective predictive model for IO (R-Model), that will be used in the prospective study phase to create a first version of the PDSS tool, an AI-based tool to provide an easy and ready-to-use access to predictive models, increasing care appropriateness, reducing the negative impacts of prolonged and toxic treatments on wellbeing and healthcare costs.\n\nThe prospective part of the project includes the collection and the analysis of multi-OMICs data from a multicentric prospective cohort of about 200 patients. This cohort will be used to validate the results obtained from the retrospective model through the creation of a new model (P-Model), which will be used to create the final PDSS tool.",[144,32,257,258],"Lung Cancer, Nonsmall Cell","Lung Adenocarcinoma",[260,261,236],"NSCLC","Artificial Intelligence","2023-01-05",{"date":264,"type":41},"2023-01-06",{"date":266,"type":41},"2022-10-01",{"date":268,"type":20},"2027-10-01",{"name":270,"class":74},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",4]